As summarized in Healio.com, LXB improved all measures of function and work productivity among patients with idiopathic hypersomnia, according to findings presented at the American Neurological Association Annual Meeting.
According to Healio, the treatment (calcium, magnesium, potassium and sodium oxybates; Jazz Pharmaceuticals Inc.), also referred to as lower-sodium oxybate (LXB) and Xywav, has the same active moiety at the same concentration as sodium oxybate but features 92% less sodium. The FDA approved LXB in August for adults with idiopathic hypersomnia.
“In a [prior] double-blind, placebo-controlled randomized withdrawal study in adults with idiopathic hypersomnia, LXB demonstrated clinically and statistically meaningful improvement of excessive daytime sleepiness, overall symptom severity and self-reported patient global impression of change,” Michael J. Thorpy, MD, professor of neurology at Albert Einstein College of Medicine and director of the Sleep-Wake Disorders Center in the department of neurology at Montefiore Medical Center, both in New York, said during a virtual presentation. “The objective of this study analysis was to evaluate the effects of LXB on functioning and work productivity in participants with idiopathic hypersomnia…LXB demonstrated improvement in measures of functioning and work productivity in study participants with idiopathic hypersomnia.”
